260 related articles for article (PubMed ID: 31653704)
21. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S; Salphati L; Gomez-Zepeda D; Wanek T; Chen L; Chu X; Kunta J; Mezler M; Menet MC; Chasseigneaux S; Declèves X; Langer O; Pierre E; DiLoreto K; Hoft C; Laplanche L; Pang J; Pereira T; Andonian C; Simic D; Rode A; Yabut J; Zhang X; Scheer N
Mol Pharmacol; 2016 May; 89(5):492-504. PubMed ID: 26893303
[TBL] [Abstract][Full Text] [Related]
22. Bisphenol A Inhibits the Transporter Function of the Blood-Brain Barrier by Directly Interacting with the ABC Transporter Breast Cancer Resistance Protein (BCRP).
Engdahl E; van Schijndel MDM; Voulgaris D; Di Criscio M; Ramsbottom KA; Rigden DJ; Herland A; Rüegg J
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073890
[TBL] [Abstract][Full Text] [Related]
23. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
24. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
26. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
27. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
28. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
30. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Barghout SH; Aman A; Nouri K; Blatman Z; Arevalo K; Thomas GE; MacLean N; Hurren R; Ketela T; Saini M; Abohawya M; Kiyota T; Al-Awar R; Schimmer AD
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33476303
[TBL] [Abstract][Full Text] [Related]
31. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
32. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
33. Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Sawangrat K; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2018 Nov; 107(11):2946-2956. PubMed ID: 30053556
[TBL] [Abstract][Full Text] [Related]
34. (67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity.
Sivapackiam J; Harpstrite SE; Prior JL; Mattingly S; Sharma V
Nucl Med Biol; 2016 Mar; 43(3):191-7. PubMed ID: 26924499
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein.
Miyamoto R; Nozawa T; Shiozuka K; Tabata K
J Pharm Sci; 2019 Mar; 108(3):1085-1089. PubMed ID: 30339864
[TBL] [Abstract][Full Text] [Related]
36. Transcription factor-mediated regulation of the BCRP/
Gorczyca L; Aleksunes LM
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):239-253. PubMed ID: 32077332
[No Abstract] [Full Text] [Related]
37. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
38. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Hasanabady MH; Kalalinia F
J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
[TBL] [Abstract][Full Text] [Related]
39. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
